Kazuo Yamashita

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Respiratory Syndrome Coronavirus

Epidermal Growth Factor Receptor

Top Venues

Science advances

Cancer research

This page only lists publications with an associated author ORCID identifier.

Publications

Yuto Naoi, Takao Morinaga, Joji Nagasaki, Ryo Ariyasu, Youki Ueda, Kazuo Yamashita, Wenhao Zhou, Shusuke Kawashima, Katsushige Kawase, Akiko Honobe-Tabuchi, Takehiro Ohnuma, Tatsuyoshi Kawamura, Yoshiyasu Umeda, Yu Kawahara, Yasuhiro Nakamura, Yukiko Kiniwa, Osamu Yamasaki, Satoshi Fukushima, Masahito Kawazu, Yutaka Suzuki, Hiroyoshi Nishikawa, Toyoyuki Hanazawa, Mizuo Ando, Takashi Inozume, Yosuke Togashi
CD106 in tumor-specific exhausted CD8+ T cells mediates immunosuppression by inhibiting TCR signaling. Cancer research (2024)
Yuto Naoi, Takao Morinaga, Joji Nagasaki, Ryo Ariyasu, Youki Ueda, Kazuo Yamashita, Wenhao Zhou, Shusuke Kawashima, Katsushige Kawase, Akiko Honobe-Tabuchi, Takehiro Ohnuma, Tatsuyoshi Kawamura, Yoshiyasu Umeda, Yu Kawahara, Yasuhiro Nakamura, Yukiko Kiniwa, Osamu Yamasaki, Satoshi Fukushima, Masahito Kawazu, Yutaka Suzuki, Hiroyoshi Nishikawa, Toyoyuki Hanazawa, Mizuo Ando, Takashi Inozume, Yosuke Togashi
CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling. Cancer research 84 (13) (2024)
Yujiro Naito, Syohei Koyama, Kentaro Masuhiro, Takashi Hirai, Takeshi Uenami, Takako Inoue, Akio Osa, Hirotomo Machiyama, Go Watanabe, Nicolas Sax, Jordan Villa, Yumi Kinugasa-Katayama, Satoshi Nojima, Moto Yaga, Yuki Hosono, Daisuke Okuzaki, Shingo Satoh, Takeshi Tsuda, Yoshimitsu Nakanishi, Yasuhiko Suga, Takayoshi Morita, Kiyoharu Fukushima, Masayuki Nishide, Takayuki Shiroyama, Kotaro Miyake, Kota Iwahori, Haruhiko Hirata, Izumi Nagatomo, Yukihiro Yano, Motohiro Tamiya, Toru Kumagai, Norihiko Takemoto, Hidenori Inohara, Sho Yamasaki, Kazuo Yamashita, Taiki Aoshi, Esra A Akbay, Naoki Hosen, Yasushi Shintani, Hyota Takamatsu, Masahide Mori, Yoshito Takeda, Atsushi Kumanogoh
Tumor-derived semaphorin 4A improves PD-1-blocking antibody efficacy by enhancing CD8 + T cell cytotoxicity and proliferation. Science advances 9 (20) (2023)
Yujiro Naito, Syohei Koyama, Kentaro Masuhiro, Takashi Hirai, Takeshi Uenami, Takako Inoue, Akio Osa, Hirotomo Machiyama, Go Watanabe, Nicolas Sax, Jordan Villa, Yumi Kinugasa-Katayama, Satoshi Nojima, Moto Yaga, Yuki Hosono, Daisuke Okuzaki, Shingo Satoh, Takeshi Tsuda, Yoshimitsu Nakanishi, Yasuhiko Suga, Takayoshi Morita, Kiyoharu Fukushima, Masayuki Nishide, Takayuki Shiroyama, Kotaro Miyake, Kota Iwahori, Haruhiko Hirata, Izumi Nagatomo, Yukihiro Yano, Motohiro Tamiya, Toru Kumagai, Norihiko Takemoto, Hidenori Inohara, Sho Yamasaki, Kazuo Yamashita, Taiki Aoshi, Esra A Akbay, Naoki Hosen, Yasushi Shintani, Hyota Takamatsu, Masahide Mori, Yoshito Takeda, Atsushi Kumanogoh
Tumor-derived semaphorin 4A improves PD-1-blocking antibody efficacy by enhancing CD8 + T cell cytotoxicity and proliferation. Science advances 9 (20) (2023)
Taishi Onodera, Nicolas Sax, Takashi Sato, Yu Adachi, Ryutaro Kotaki, Takeshi Inoue, Ryo Shinnakasu, Takayuki Nakagawa, Shuetsu Fukushi, Tommy Terooatea, Mai Yoshikawa, Keisuke Tonouchi, Takaki Nagakura, Saya Moriyama, Takayuki Matsumura, Masanori Isogawa, Kazutaka Terahara, Tomohiro Takano, Lin Sun, Ayae Nishiyama, Shinnya Omoto, Masaharu Shinkai, Tomohiro Kurosaki, Kazuo Yamashita, Yoshimasa Takahashi
CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopes. Science advances 9 (24) (2023)
Yujiro Naito, Syohei Koyama, Kentaro Masuhiro, Takashi Hirai, Takeshi Uenami, Takako Inoue, Akio Osa, Hirotomo Machiyama, Go Watanabe, Nicolas Sax, Jordan Villa, Yumi Kinugasa-Katayama, Satoshi Nojima, Moto Yaga, Yuki Hosono, Daisuke Okuzaki, Shingo Satoh, Takeshi Tsuda, Yoshimitsu Nakanishi, Yasuhiko Suga, Takayoshi Morita, Kiyoharu Fukushima, Masayuki Nishide, Takayuki Shiroyama, Kotaro Miyake, Kota Iwahori, Haruhiko Hirata, Izumi Nagatomo, Yukihiro Yano, Motohiro Tamiya, Toru Kumagai, Norihiko Takemoto, Hidenori Inohara, Sho Yamasaki, Kazuo Yamashita, Taiki Aoshi, Esra A Akbay, Naoki Hosen, Yasushi Shintani, Hyota Takamatsu, Masahide Mori, Yoshito Takeda, Atsushi Kumanogoh
Tumor-derived semaphorin 4A improves PD-1-blocking antibody efficacy by enhancing CD8 + T cell cytotoxicity and proliferation. Science advances 9 (20) (2023)